
CLAIMS

1. A compound represented by the following general formula (I')

[Formula 269]



(I')

(wherein in formula (I'),

W represents the formula $-CR^{15}R^{16}-$, the formula $-CR^{11}R^{12}CR^{13}R^{14}-$, or the formula $--CH_2CR^{17}R^{18}CH_2-$;

R^{15} represents a hydrogen atom, C_{1-4} alkyl, or phenyl;

R^{16} represents a hydrogen atom or C_{1-4} alkyl;

provided that R^{15} and R^{16}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane;

R^{11} represents a hydrogen atom, a fluorine atom, C_{1-4} alkyl, or phenyl;

R^{12} represents a hydrogen atom, a fluorine atom, or C_{1-4} alkyl;

provided that R^{11} and R^{12}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane or a 4- to 8-membered saturated heterocycle containing an oxygen atom;

R^{13} represents a hydrogen atom, carbamoyl, C_{1-4} alkyl (the C_{1-4} alkyl is optionally substituted by one group selected from the group consisting of hydroxy, C_{1-3} alkoxy, and di-C_{1-3} alkylamino), halo-C_{1-4} alkyl, phenyl, pyridyl, benzyl, or phenethyl;

R^{14} represents a hydrogen atom, C_{1-4} alkyl, or halo-C_{1-4} alkyl;

provided that R^{13} and R^{14}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane, a 4- to 8-membered saturated heterocycle containing an oxygen atom, or a 4- to 8-membered saturated heterocycle containing a nitrogen atom (the 4- to 8-membered saturated heterocycle containing a nitrogen atom is optionally substituted by one or two

groups which are the same or different and are selected from the group consisting of methyl, benzyl, phenylcarbonyl, and oxo);

provided that said R^{12} and R^{13}, together with the adjacent carbon atoms, optionally form C_{3-8} cycloalkane;

R^{17} represents a hydrogen atom or C_{1-4} alkyl;

R^{18} represents a hydrogen atom or C_{1-4} alkyl;

provided that R^{17} and R^{18}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane;

Y represents a single bond or C_{1-6} alkanediyl (the C_{1-6} alkanediyl is optionally substituted by one hydroxy, and one of the carbon atoms in the C_{1-6} alkanediyl is optionally substituted by C_{3-6} cycloalkane-1,1-diyl);

R^2 represents a hydrogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl {the C_{3-8} cycloalkyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl (the C_{1-6} alkyl is optionally substituted by one phenyl), phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and halo-C_{1-6} alkyl), C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl, phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl), and pyridyl (the pyridyl is optionally substituted by one halogen atom)], C_{3-8} cycloalkoxy, phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl, and halo-C_{1-6} alkyl), and pyridyloxy (the pyridyloxy is optionally substitduted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl, and halo-C_{1-6} alkyl)}, phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from group α3 of substituents), naphthyl, indanyl, tetrahydronaphthyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl [the pyrazolyl, imidazolyl, isoxazolyl, and oxazolyl are optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl and phenyl (the phenyl is optionally substituted by

one group selected from the group consisting of a halogen atom and C_{1-6} alkyl)], thiazoyl [the thiazoyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl, phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl), and morpholino], pyridyl (the pyridyl is optionally substituted by one or two groups which are the same or different and are selected from group α5 of substituents), pyridazinyl, pyrimidinyl, pyrazinyl [the pyridazinyl, pyrimidinyl, and pyrazinyl are optionally substituted by one group selected from the group consisting of C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl, C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl), and phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, and C_{3-8} cycloalkyl)], benzothiophenyl, quinolyl, methylenedioxyphenyl (the methylenedioxyphenyl is optionally substituted by one or two fluorine atoms), 4- to 8-membered saturated heterocyclyl containing a nitrogen atom [the 4- to 8-membered saturated heterocyclyl containing a nitrogen atom is optionally substituted by one group selected from the group consisting of pyrimidinyl, phenyl-C_{1-3} alkyl, C_{3-8} cycloalkyl-C_{1-3} alkylcarbonyl, and phenyl-C_{1-3} alkoxycarbonyl], or the following formula (I'')

[Formula 270]



(I'')

[wherein in formula (I''),

R^5 represents a hydrogen atom or C_{1-3} alkyl, and R^6 represents phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, and phenyl)],

group α3 of substituents consists of hydroxy, cyano, carboxy, a halogen atom, C_{1-6} alkyl {the C_{1-6} alkyl is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl, phenyl, C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one C_{1-6} alkyl)], phenoxy (the phenoxy is optionally substituted by one C_{1-6} alkyl), and pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of C_{1-6} alkyl and halo-

C_{1-6} alkyl)}, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one or two halogen atoms), C_{3-8} cycloalkenyl (the C_{3-8} cycloalkenyl is optionally substituted by one or two halogen atoms), phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from group α4 of substituents), thienyl (the thienyl is optionally substituted by one C_{1-6} alkyl), pyrazolyl (the pyrazolyl is optionally substituted by one C_{1-6} alkyl), isoxazolyl, thiazoyl (the thiazoyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy), pyridyl (the pyridyl is optionally substituted by one group selected from the group consisting of carboxy, hydroxy, amino, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, and C_{1-6} alkylsulfonyl), pyrimidinyl (the pyrimidinyl is optionally substituted by one amino), quinolyl, C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of carboxy, hydroxy, carbamoyl, C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one C_{1-6} alkyl), phenyl (the phenyl is optionally substituted by one group selected from the group consisting of hydroxy, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, and di-C_{1-6} alkylamino), pyridyl (the pyridyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl), oxazolyl (the oxazolyl is optionally substituted by one or two C_{1-6} alkyls), pyrazolyl (the pyrazolyl is optionally substituted by one or two C_{1-6} alkyls), thiazoyl (the thiazoyl is optionally substituted by one C_{1-6} alkyl), indazolyl (the indazolyl is optionally substituted by one C_{1-6} alkyl), benzotriazolyl, imidazothiazoyl, and di-C_{1-6} alkylamino], halo-C_{1-6} alkoxy, C_{2-6} alkenyloxy, C_{3-8} cycloalkoxy, phenoxy (the phenoxy is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, and C_{3-8} cycloalkyl), pyrimidinyloxy, piperazinyl (the piperazinyl is optionally substituted by one C_{1-6} alkyl), mono-C_{1-6} alkylaminocarbonyl (the C_{1-6} alkyl in the mono-C_{1-6} alkylaminocarbonyl is

optionally substituted by one group selected from the group consisting of carboxy, hydroxy, di-C_{1-6} alkylamino, pyridyl, phenyl, and 2-oxopyrrolidinyl), di-C_{1-6} alkylaminocarbonyl (where the two C_{1-6} alkyls in the di-C_{1-6} alkylaminocarbonyl, together with the adjacent nitrogen atom, optionally form a 4- to 8-membered saturated heterocycle containing a nitrogen atom), C_{1-6} alkylsulfanyl, and C_{1-6} alkylsulfonyl;

group α4 of substituents consists of carboxy, cyano, hydroxy, sulfamoyl, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, C_{1-6} alkylcarbonyl, di-C_{1-6} alkylaminocarbonyl, C_{1-6} alkylsulfonyl, mono-C_{1-6} alkylaminosulfonyl (the C_{1-6} alkyl in the mono-C_{1-6} alkylaminosulfonyl is optionally substituted by one hydroxy), and di-C_{1-6} alkylaminosulfonyl;

group α5 of substituents consists of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one C_{1-6} alkyl) and phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl)], halo-C_{1-6} alkoxy, phenyl (the phenyl is optionally substituted by one group selected from group α6 of substituents), pyridyl, phenoxy [the phenoxy is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of a halogen atom, cyano, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one phenyl), and halo-C_{1-6} alkoxy], pyridyloxy (the pyridyloxy is optionally substituted by one C_{1-6} alkyl), and phenylsulfanyl (the phenylsulfanyl is optionally substituted by one halogen atom);

group α6 of substituents consists of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy;

Y^4 represents C_{1-4} alkanediyl;

R^3 represents a hydrogen atom or methyl;

R^4 represents -COOH, -CONHOH, or tetrazolyl);

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein in the aforementioned general formula

(I'),

Y^4 is methanediyl,

R^3 is a hydrogen atom,


R^4 is -COOH,

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 wherein in the aforementioned general formula (I'),

W is the formula $-CR^{15}R^{16}-$, and the compound is represented by general formula (I'-1):

[Formula 271]



(I'-1)

(wherein in formula (I'-1),

R^{15} is a hydrogen atom, C_{1-4} alkyl, or phenyl,

R^{16} is a hydrogen atom or C_{1-4} alkyl,


provided that R^{15} and R^{16}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane),

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 2 wherein in the aforementioned general formula (I'),

W is the formula $-CR^{11}R^{12}CR^{13}R^{14}-$, and the compound is represented by general formula (I'-2):

[Formula 272]



(I'-2)

(wherein in formula (I'-2),

R^{11} is a hydrogen atom, a fluorine atom, C_{1-4} alkyl, or phenyl,

R^{12} is a hydrogen atom, a fluorine atom, or C_{1-4} alkyl,

provided that R^{11} and R^{12}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane or a 4- to 8-membered saturated heterocycle containing an oxygen atom;

R^{13} is a hydrogen atom, carbamoyl, C_{1-4} alkyl (the C_{1-4} alkyl is optionally substituted by one group selected from the group consisting of hydroxy, C_{1-3} alkoxy, and di-C_{1-3} alkylamino), halo-C_{1-4} alkyl, phenyl, pyridyl, benzyl, or phenethyl;

R^{14} is a hydrogen atom, C_{1-4} alkyl, or halo-C_{1-4} alkyl,

provided that R^{13} and R^{14}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane, a 4- to 8-membered saturated heterocycle containing an oxygen atom, or a 4- to 8-membered saturated heterocycle containing a nitrogen atom (the 4- to 8-membered saturated heterocycle containing a nitrogen atom is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of methyl, benzyl, phenylcarbonyl, and oxo),

provided that the aforementioned R^{12} and R^{13}, together with the adjacent carbon atoms, optionally form C_{3-8} cycloalkane),

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4 wherein in the aforementioned general formula (I'-2),

Y is a single bond or C_{1-6} alkanediyl (one of the carbon atoms in the C_{1-6} alkanediyl is optionally substituted by C_{3-6} cycloalkane-1,1-diyl),

R^2 is C_{3-8} cycloalkyl {the C_{3-8} cycloalkyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl (the C_{1-6} alkyl is optionally substituted by one phenyl), phenyl (the phenyl is optionally substituted by one halo-C_{1-6} alkyl), C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl, phenyl (the phenyl is

optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl), and pyridyl (the pyridyl is optionally substituted by one halogen atom)], C_{3-8} cycloalkoxy, phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl, and halo-C_{1-6} alkyl), and pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl, and halo-C_{1-6} alkyl)}, phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from the aforementioned group α3 of substituents), naphthyl, indanyl, tetrahydronaphthyl, pyrazolyl [the pyrazolyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl and phenyl (the phenyl is optionally substituted by one C_{1-6} alkyl)], imidazolyl (the imidazolyl is optionally substituted by one group selected from the group consisting of C_{1-6} alkyl and phenyl), isoxazolyl [the isoxazolyl is optionally substituted by one phenyl (the phenyl is optionally substituted by one halogen atom)], oxazolyl (the oxazolyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl and phenyl), thiazoyl (the thiazoyl is optionally substituted by one group selected from the group consisting of C_{1-6} alkyl, phenyl, and morpholino), pyridyl (the pyridyl is optionally substituted by one or two groups which are the same or different and are selected from the aforementioned group α5 of substituents), pyridazinyl [the pyridazinyl is optionally substituted by one C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl)], pyrimidinyl [the pyrimidinyl is optionally substituted by one group selected from the group consisting of halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl, and phenoxy (the phenoxy is optionally substituted by one C_{1-6} alkyl)], pyrazinyl [the pyrazinyl is optionally substituted by one group selected from the group consisting of C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by C_{3-8} cycloalkyl) and phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, and C_{3-8} cycloalkyl)], benzothiophenyl, quinolyl, or methylenedioxyphenyl (the methylenedioxyphenyl is optionally substituted by one or two fluorine atoms),

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 5 wherein in the aforementioned general formula (I'-2),

R^{11} is a hydrogen atom,

R^{12} is a hydrogen atom,

R^{13} is a hydrogen atom,

R^{14} is a hydrogen atom,

Y is methanediyl,

R^2 is

phenyl {the phenyl is substituted by one group selected from the group consisting of phenyl [the phenyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of carboxy, cyano, hydroxy, sulfamoyl, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, C_{1-6} alkylcarbonyl, di-C_{1-6} alkylaminocarbonyl, C_{1-6} alkylsulfonyl, mono-C_{1-6} alkylaminosulfonyl (the C_{1-6} alkyl in the mono-C_{1-6} alkylaminosulfonyl is optionally substituted by one hydroxy), and di-C_{1-6} alkylaminosulfonyl], pyridyl (the pyridyl is optionally substituted by one group selected from the group consisting of carboxy, hydroxy, amino, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, and C_{1-6} alkylsulfonyl), phenoxy (the phenoxy is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), and pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, and C_{3-8} cycloalkyl), and may further be substituted by one halogen atom};

pyridyl {the pyridyl is substituted by one group selected from the group consisting of phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), pyridyl, phenoxy [the phenoxy is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of a halogen atom, cyano, C_{1-6}

alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one phenyl), and halo-C_{1-6} alkoxy], and pyridyloxy (the pyridyloxy is optionally substituted by one C_{1-6} alkyl), and may further be substitduted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl}; or

pyrazinyl which is substituted by one phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, and C_{3-8} cycloalkyl), or a pharmaceutically acceptable salt thereof.

7. The following compound according to claim 1:

N-{[4-hydroxy-2-oxo-1-(4-phenoxybenzyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(4-hydroxy-1-{[6-(4-methylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({4-hydroxy-2-oxo-1-[(6-phenoxy-3-pyridinyl)methyl]-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-({1-[4-(4-fluorophenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-({4-hydroxy-1-[4-(4-methylphenoxy)benzyl]-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[6-(4-cyanophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({4-hydroxy-2-oxo-1-[4-(2-pyrimidinyloxy)benzyl]-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[6-(4-fluorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-chlorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-({6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl}methyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(4-hydroxy-1-{[6-(3-methylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-

pyridinyl)carbonyl]glycine;

N-[(1-{[6-(3-fluorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({4-hydroxy-1-[4-(3-methylphenoxy)benzyl]-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-({1-[4-(3-fluorophenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[5-(4-fluorophenoxy)-2-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[5-(4-methylphenoxy)-2-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({1-[4-(4-chlorophenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(4-hydroxy-1-{4-[(6-methyl-3-pyridinyl)oxy]benzyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(2-fluorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[6-(2-methylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({1-[4-(2-fluorophenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-({4-hydroxy-1-[4-(2-methylphenoxy)benzyl]-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[6-(3-chlorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-({6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl}methyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-({4-hydroxy-1-[4-(3-methoxyphenoxy)benzyl]-2-oxo-1,2,5,6-tetrahydro-3-

pyridinyl}carbonyl)glycine;

N-{[4-hydroxy-2-oxo-1-({6-[3-(trifluoromethoxy)phenoxy]-3-pyridinyl}methyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(1-{4-[(5-fluoro-2-pyridinyl)oxy]benzyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{4-[(5-chloro-2-pyridinyl)oxy]benzyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-cyclopropylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{4-[(5-methyl-2-pyridinyl)oxy]benzyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-(4-{[5-(trifluoromethyl)-2-pyridinyl]oxy}benzyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-{[4-hydroxy-1-({5-methyl-6-[(6-methyl-3-pyridinyl)oxy]-3-pyridinyl}methyl)-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(1-{[5-(4-chlorophenoxy)-2-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[6-(3-methoxyphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{4-[(6-chloro-3-pyridinyl)oxy]benzyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-({5-[4-(trifluoromethyl)phenoxy]-2-pyridinyl}methyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-{[4-hydroxy-2-oxo-1-(4-{[6-(trifluoromethyl)-3-pyridinyl]oxy}benzyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(1-{[6-(3-chloro-4-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(3-fluoro-4-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-

tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-fluoro-3-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-ethylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-2-oxo-1-{[6-(4-propylphenoxy)-3-pyridinyl]methyl}-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[6-(4-isopropylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[5-(4-methylphenoxy)-2-pyrazinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({1-[4-(3,4-dimethylphenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[5-chloro-6-(4-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[5-fluoro-6-(4-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{4-[(5-cyclopropyl-2-pyridinyl)oxy]benzyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[2-(4-methylphenoxy)-5-pyrimidinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-chlorophenoxy)-5-methyl-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;


N-[(1-{[5-(4-chlorophenoxy)-2-pyrazinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine; or

N-[(1-{[5-(4-cyclopropylphenoxy)-2-pyrazinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine,

or a pharmaceutically acceptable salt thereof.

8. A compound having the aforementioned general formula (I'), wherein W is the formula $-CR^{11}R^{12}CR^{13}R^{14}-$, and the compound is represented by general formula (I):

[Formula 273]



(I)

(wherein in formula (I),

R^{11} is a hydrogen atom, C_{1-4} alkyl, or phenyl,

R^{12} is a hydrogen atom or C_{1-4} alkyl,

provided that R^{11} and R^{12}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane or a 4- to 8-membered saturated heterocycle containing an oxygen atom;

R^{13} is a hydrogen atom, C_{1-4} alkyl, halo-C_{1-4} alkyl, phenyl, benzyl, or phenethyl,

R^{14} is a hydrogen atom or C_{1-4} alkyl,

provided that R^{13} and R^{14}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane or a 4- to 8-membered saturated heterocycle containing an oxygen atom,

provided that the aforementioned R^{12} and R^{13}, together with the adjacent carbon atoms, optionally form C_{3-8} cycloalkane;

Y is a single bond or C_{1-6} alkanediyl (one of the carbon atoms in the C_{1-6} alkanediyl is optionally substituted by C_{3-6} cycloalkane-1,1-diyl);

R^2 is C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one group selected from the group consisting of phenyl and benzyl), phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from group α1 of substituents), naphthyl, indanyl, tetrahydronaphthyl, pyrazolyl [the pyrazolyl is substituted by one phenyl (the phenyl is optionally substituted by one C_{1-6} alkyl) and may further be substituted by one C_{1-6} alkyl], imidazolyl (the imidazolyl is substituted by one phenyl), isoxazolyl [the isoxazolyl is substituted by one phenyl (the phenyl is optionally substituted by

one halogen atom)], oxazolyl (the oxazolyl is substituted by one phenyl and may further be substituted by one C_{1-6} alkyl), thiazoyl (the thiazoyl is substituted by one phenyl), pyridyl [the pyridyl is substituted by one group selected from the group consisting of phenyl, phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, cyano, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), and phenylsulfanyl (the phenylsulfanyl is optionally substituted by one halogen atom)], pyrimidinyl (the pyrimidinyl is substituted by one group selected from the group consisting of cyclohexyl and phenyl), benzothiophenyl, quinolyl, or methylenedioxyphenyl (the methylenedioxyphenyl is optionally substituted by one or two fluorine atoms);

group α1 of substituents consists of a halogen atom, C_{1-6} alkyl {the C_{1-6} alkyl is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl, phenyl, and C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one C_{1-6} alkyl)]}, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from group α2 of substituents), thienyl, pyrazolyl (the pyrazolyl is optionally substituted by one C_{1-6} alkyl), isoxazolyl, thiazoyl (the thiazoyl is optionally substituted by one or two C_{1-6} alkyls), pyridyl (the pyridyl is optionally substituted by one group selected from the group consisting of C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), quinolyl, C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl and phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl)], halo-C_{1-6} alkoxy, C_{2-6} alkenyloxy, C_{3-8} cycloalkoxy, phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, and halo-C_{1-6} alkyl), and C_{1-6} alkylsulfanyl;

group α2 of substituents consists of a halogen atom, cyano, hydroxy, C_{1-6} alkyl, halo-C_{1-6}

alkyl, phenyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, C_{1-6} alkylcarbonyl, and di-C_{1-6} alkylaminosulfonyl),

or a pharmaceutically acceptable salt thereof.

9. A medicine comprising the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof as an active ingredient.

10. A PHD2 inhibitor comprising the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof as an active ingredient.


11. An EPO production promoter comprising the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof as an active ingredient.

12. A drug for preventing or treating anemia comprising the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof as an active ingredient.

CLAIMS

1. A compound represented by the following general formula (I')

[Formula 269]



(I')

(wherein in formula (I'),

W represents the formula $-CR^{15}R^{16}-$, the formula $-CR^{11}R^{12}CR^{13}R^{14}-$, or the formula $-CH_2CR^{17}R^{18}CH_2-$;

R^{15} represents a hydrogen atom, C_{1-4} alkyl, or phenyl;

R^{16} represents a hydrogen atom or C_{1-4} alkyl;

provided that R^{15} and R^{16}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane;

R^{11} represents a hydrogen atom, a fluorine atom, C_{1-4} alkyl, or phenyl;

R^{12} represents a hydrogen atom, a fluorine atom, or C_{1-4} alkyl;

provided that R^{11} and R^{12}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane or a 4- to 8-membered saturated heterocycle containing an oxygen atom;

R^{13} represents a hydrogen atom, carbamoyl, C_{1-4} alkyl (the C_{1-4} alkyl is optionally substituted by one group selected from the group consisting of hydroxy, C_{1-3} alkoxy, and di-C_{1-3} alkylamino), halo-C_{1-4} alkyl, phenyl, pyridyl, benzyl, or phenethyl;

R^{14} represents a hydrogen atom, C_{1-4} alkyl, or halo-C_{1-4} alkyl;

provided that R^{13} and R^{14}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane, a 4- to 8-membered saturated heterocycle containing an oxygen atom, or a 4- to 8-membered saturated heterocycle containing a nitrogen atom (the 4- to

8-membered saturated heterocycle containing a nitrogen atom is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of methyl, benzyl, phenylcarbonyl, and oxo);

provided that said R^{12} and R^{13}, together with the adjacent carbon atoms, optionally form C_{3-8} cycloalkane;

R^{17} represents a hydrogen atom or C_{1-4} alkyl;

R^{18} represents a hydrogen atom or C_{1-4} alkyl;


provided that R^{17} and R^{18}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane;

Y represents a single bond or C_{1-6} alkanediyl (the C_{1-6} alkanediyl is optionally substituted by one hydroxy, and one of the carbon atoms in the C_{1-6} alkanediyl is optionally substituted by C_{3-6} cycloalkane-1,1-diyl);

R^2 represents a hydrogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl {the C_{3-8} cycloalkyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl (the C_{1-6} alkyl is optionally substituted by one phenyl), phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and halo-C_{1-6} alkyl), C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl, phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl), and pyridyl (the pyridyl is optionally substituted by one halogen atom)], C_{3-8} cycloalkoxy, phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl, and halo-C_{1-6} alkyl), and pyridyloxy (the pyridyloxy is optionally substitduted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl, and halo-C_{1-6} alkyl)}, phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from group α3 of substituents), naphthyl, indanyl, tetrahydronaphthyl, pyrazolyl, imidazolyl,

isoxazolyl, oxazolyl [the pyrazolyl, imidazolyl, isoxazolyl, and oxazolyl are optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl and phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl)], thiazoyl [the thiazoyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl, phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl), and morpholino], pyridyl (the pyridyl is optionally substituted by one or two groups which are the same or different and are selected from group α5 of substituents), pyridazinyl, pyrimidinyl, pyrazinyl [the pyridazinyl, pyrimidinyl, and pyrazinyl are optionally substituted by one group selected from the group consisting of C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl, C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl), and phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, and C_{3-8} cycloalkyl)], benzothiophenyl, quinolyl, methylenedioxyphenyl (the methylenedioxyphenyl is optionally substituted by one or two fluorine atoms), 4- to 8-membered saturated heterocyclyl containing a nitrogen atom [the 4- to 8-membered saturated heterocyclyl containing a nitrogen atom is optionally substituted by one group selected from the group consisting of pyrimidinyl, phenyl-C_{1-3} alkyl, C_{3-8} cycloalkyl-C_{1-3} alkylcarbonyl, and phenyl-C_{1-3} alkoxycarbonyl], or the following formula (I")

[Formula 270]



[wherein in formula (I''),

R^5 represents a hydrogen atom or C_{1-3} alkyl, and R^6 represents phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, and phenyl)],

group α3 of substituents consists of hydroxy, cyano, carboxy, a halogen atom, C_{1-6} alkyl {the C_{1-6} alkyl is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl, phenyl, C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one C_{1-6} alkyl)], phenoxy (the phenoxy is optionally substituted by one C_{1-6} alkyl), and pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of C_{1-6} alkyl and halo-C_{1-6} alkyl)}, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one or two halogen atoms), C_{3-8} cycloalkenyl (the C_{3-8} cycloalkenyl is optionally substituted by one or two halogen atoms), phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from group α4 of substituents), thienyl (the thienyl is optionally substituted by one C_{1-6} alkyl), pyrazolyl (the pyrazolyl is optionally substituted by one C_{1-6} alkyl), isoxazolyl, thiazoyl (the thiazoyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy), pyridyl (the pyridyl is optionally substituted by one group selected from the group consisting of carboxy, hydroxy, amino, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, and C_{1-6} alkylsulfonyl), pyrimidinyl (the pyrimidinyl is optionally substituted by one amino), quinolyl, C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of carboxy, hydroxy, carbamoyl, C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one C_{1-6} alkyl), phenyl (the phenyl is optionally substituted by one group selected from the group consisting of hydroxy, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, and di-C_{1-6} alkylamino), pyridyl (the pyridyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl), oxazolyl (the oxazolyl is optionally substituted by one or two C_{1-6} alkyls), pyrazolyl (the pyrazolyl is optionally substituted by one or two C_{1-6} alkyls), thiazoyl (the thiazoyl is optionally substituted by one C_{1-6} alkyl), indazolyl (the

indazolyl is optionally substituted by one C_{1-6} alkyl), benzotriazolyl, imidazothiazoyl, and di-C_{1-6} alkylamino], halo-C_{1-6} alkoxy, C_{2-6} alkenyloxy, C_{3-8} cycloalkoxy, phenoxy (the phenoxy is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, and C_{3-8} cycloalkyl), pyrimidinyloxy, piperazinyl (the piperazinyl is optionally substituted by one C_{1-6} alkyl), mono-C_{1-6} alkylaminocarbonyl (the C_{1-6} alkyl in the mono-C_{1-6} alkylaminocarbonyl is optionally substituted by one group selected from the group consisting of carboxy, hydroxy, di-C_{1-6} alkylamino, pyridyl, phenyl, and 2-oxopyrrolidinyl), di-C_{1-6} alkylaminocarbonyl (where the two C_{1-6} alkyls in the di-C_{1-6} alkylaminocarbonyl, together with the adjacent nitrogen atom, optionally form a 4- to 8-membered saturated heterocycle containing a nitrogen atom), C_{1-6} alkylsulfanyl, and C_{1-6} alkylsulfonyl;

group α4 of substituents consists of carboxy, cyano, hydroxy, sulfamoyl, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, C_{1-6} alkylcarbonyl, di-C_{1-6} alkylaminocarbonyl, C_{1-6} alkylsulfonyl, mono-C_{1-6} alkylaminosulfonyl (the C_{1-6} alkyl in the mono-C_{1-6} alkylaminosulfonyl is optionally substituted by one hydroxy), and di-C_{1-6} alkylaminosulfonyl;

group α5 of substituents consists of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one C_{1-6} alkyl) and phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl)], halo-C_{1-6} alkoxy, phenyl (the phenyl is optionally substituted by one group selected from group α6 of substituents), pyridyl, phenoxy [the phenoxy is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of a halogen atom,

cyano, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one phenyl), and halo-C_{1-6} alkoxy], pyridyloxy (the pyridyloxy is optionally substituted by one C_{1-6} alkyl), and phenylsulfanyl (the phenylsulfanyl is optionally substituted by one halogen atom);

group α6 of substituents consists of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy;

Y^4 represents C_{1-4} alkanediyl;

R^3 represents a hydrogen atom or methyl;

R^4 represents -COOH, -CONHOH, or tetrazolyl);

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein in the aforementioned general formula (I'),

Y^4 is methanediyl,

R^3 is a hydrogen atom,


R^4 is -COOH,

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 wherein in the aforementioned general formula (I'),

W is the formula $-CR^{15}R^{16}-$, and the compound is represented by general formula (I'-1):

[Formula 271]



(I'-1)

(wherein in formula (I'-1),

R^{15} is a hydrogen atom, C_{1-4} alkyl, or phenyl,

R^{16} is a hydrogen atom or C_{1-4} alkyl,


provided that R^{15} and R^{16}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane) ,

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 2 wherein in the aforementioned general formula (I'),

W is the formula $-CR^{11}R^{12}CR^{13}R^{14}-$, and the compound is represented by general formula (I'-2):

[Formula 272]



(I'-2)

(wherein in formula (I'-2),

R^{11} is a hydrogen atom, a fluorine atom, C_{1-4} alkyl, or phenyl,

R^{12} is a hydrogen atom, a fluorine atom, or C_{1-4} alkyl,

provided that R^{11} and R^{12}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane or a 4- to 8-membered saturated heterocycle containing an oxygen atom;

R^{13} is a hydrogen atom, carbamoyl, C_{1-4} alkyl (the C_{1-4} alkyl is optionally substituted by one group selected from the group consisting of hydroxy, C_{1-3} alkoxy, and di-C_{1-3} alkylamino), halo-C_{1-4} alkyl, phenyl, pyridyl, benzyl, or phenethyl;

R^{14} is a hydrogen atom, C_{1-4} alkyl, or halo-C_{1-4} alkyl,

provided that R^{13} and R^{14}, together with the adjacent carbon atom, optionally form C_{3-8}

cycloalkane, a 4- to 8-membered saturated heterocycle containing an oxygen atom, or a 4- to 8-membered saturated heterocycle containing a nitrogen atom (the 4- to 8-membered saturated heterocycle containing a nitrogen atom is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of methyl, benzyl, phenylcarbonyl, and oxo),
provided that the aforementioned R^{12} and R^{13}, together with the adjacent carbon atoms, optionally form C_{3-8} cycloalkane),
or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4 wherein in the aforementioned general formula (I'-2),
Y is a single bond or C_{1-6} alkanediyl (one of the carbon atoms in the C_{1-6} alkanediyl is optionally substituted by C_{3-6} cycloalkane-1,1-diyl),
R^2 is C_{3-8} cycloalkyl {the C_{3-8} cycloalkyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl (the C_{1-6} alkyl is optionally substituted by one phenyl), phenyl (the phenyl is optionally substituted by one halo-C_{1-6} alkyl), C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl, phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl), and pyridyl (the pyridyl is optionally substituted by one halogen atom)], C_{3-8} cycloalkoxy, phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl, and halo-C_{1-6} alkyl), and pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{3-8} cycloalkyl, and halo-C_{1-6} alkyl)}, phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from the aforementioned group $\alpha 3$ of substituents), naphthyl, indanyl, tetrahydronaphthyl, pyrazolyl [the pyrazolyl is

optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl and phenyl (the phenyl is optionally substituted by one C_{1-6} alkyl)], imidazolyl (the imidazolyl is optionally substituted by one group selected from the group consisting of C_{1-6} alkyl and phenyl), isoxazolyl [the isoxazolyl is optionally substituted by one phenyl (the phenyl is optionally substituted by one halogen atom)], oxazolyl (the oxazolyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of C_{1-6} alkyl and phenyl), thiazoyl (the thiazoyl is optionally substituted by one group selected from the group consisting of C_{1-6} alkyl, phenyl, and morpholino), pyridyl (the pyridyl is optionally substituted by one or two groups which are the same or different and are selected from the aforementioned group $\alpha 5$ of substituents), pyridazinyl [the pyridazinyl is optionally substituted by one C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl)], pyrimidinyl [the pyrimidinyl is optionally substituted by one group selected from the group consisting of halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl, and phenoxy (the phenoxy is optionally substituted by one C_{1-6} alkyl)], pyrazinyl [the pyrazinyl is optionally substituted by one group selected from the group consisting of C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl) and phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, and C_{3-8} cycloalkyl)], benzothiophenyl, quinolyl, or methylenedioxyphenyl (the methylenedioxyphenyl is optionally substituted by one or two fluorine atoms),
or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 5 wherein in the aforementioned general formula (I'-2),

R^{11} is a hydrogen atom,

R^{12} is a hydrogen atom,

R^{13} is a hydrogen atom,

R^{14} is a hydrogen atom,

Y is methanediyl,

R^2 is

phenyl {the phenyl is substituted by one group selected from the group consisting of phenyl [the phenyl is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of carboxy, cyano, hydroxy, sulfamoyl, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, C_{1-6} alkylcarbonyl, di-C_{1-6} alkylaminocarbonyl, C_{1-6} alkylsulfonyl, mono-C_{1-6} alkylaminosulfonyl (the C_{1-6} alkyl in the mono-C_{1-6} alkylaminosulfonyl is optionally substituted by one hydroxy), and di-C_{1-6} alkylaminosulfonyl], pyridyl (the pyridyl is optionally substituted by one group selected from the group consisting of carboxy, hydroxy, amino, a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, and C_{1-6} alkylsulfonyl), phenoxy (the phenoxy is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of a halogen atom, C_{1-6} alkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), and pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, and C_{3-8} cycloalkyl), and may further be substituted by one halogen atom};
pyridyl {the pyridyl is substituted by one group selected from the group consisting of phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), pyridyl, phenoxy [the phenoxy is optionally substituted by one or two groups which are the same or different and are selected from the group consisting of a halogen atom, cyano, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy (the C_{1-6} alkoxy is optionally substituted by one phenyl), and halo-C_{1-6} alkoxy], and pyridyloxy (the pyridyloxy is optionally substituted by one C_{1-6} alkyl), and may further

be substitduted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl}; or

pyrazinyl which is substituted by one phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, and C_{3-8} cycloalkyl), or a pharmaceutically acceptable salt thereof.

7. The following compound according to claim 1:

N-{[4-hydroxy-2-oxo-1-(4-phenoxybenzyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(4-hydroxy-1-{[6-(4-methylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({4-hydroxy-2-oxo-1-[(6-phenoxy-3-pyridinyl)methyl]-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-({1-[4-(4-fluorophenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-({4-hydroxy-1-[4-(4-methylphenoxy)benzyl]-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[6-(4-cyanophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({4-hydroxy-2-oxo-1-[4-(2-pyrimidinyloxy)benzyl]-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[6-(4-fluorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-chlorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-({6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl}methyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(4-hydroxy-1-{[6-(3-methylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(3-fluorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({4-hydroxy-1-[4-(3-methylphenoxy)benzyl]-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-({1-[4-(3-fluorophenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[5-(4-fluorophenoxy)-2-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[5-(4-methylphenoxy)-2-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({1-[4-(4-chlorophenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(4-hydroxy-1-{4-[(6-methyl-3-pyridinyl)oxy]benzyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(2-fluorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[6-(2-methylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({1-[4-(2-fluorophenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-({4-hydroxy-1-[4-(2-methylphenoxy)benzyl]-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[6-(3-chlorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-({6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl}methyl)-1,2,5,6-t

etrahydro-3-pyridinyl]carbonyl}glycine;

N-({4-hydroxy-1-[4-(3-methoxyphenoxy)benzyl]-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-{[4-hydroxy-2-oxo-1-({6-[3-(trifluoromethoxy)phenoxy]-3-pyridinyl}methyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(1-{4-[(5-fluoro-2-pyridinyl)oxy]benzyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{4-[(5-chloro-2-pyridinyl)oxy]benzyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-cyclopropylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{4-[(5-methyl-2-pyridinyl)oxy]benzyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-(4-{[5-(trifluoromethyl)-2-pyridinyl]oxy}benzyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-{[4-hydroxy-1-({5-methyl-6-[(6-methyl-3-pyridinyl)oxy]-3-pyridinyl}methyl)-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(1-{[5-(4-chlorophenoxy)-2-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[6-(3-methoxyphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{4-[(6-chloro-3-pyridinyl)oxy]benzyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-{[4-hydroxy-2-oxo-1-({5-[4-(trifluoromethyl)phenoxy]-2-pyridinyl}methyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-{[4-hydroxy-2-oxo-1-(4-{[6-(trifluoromethyl)-3-pyridinyl]oxy}benzyl)-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl}glycine;

N-[(1-{[6-(3-chloro-4-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(3-fluoro-4-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-fluoro-3-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-ethylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-2-oxo-1-{[6-(4-propylphenoxy)-3-pyridinyl]methyl}-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[6-(4-isopropylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[5-(4-methylphenoxy)-2-pyrazinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-({1-[4-(3,4-dimethylphenoxy)benzyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl}carbonyl)glycine;

N-[(1-{[5-chloro-6-(4-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[5-fluoro-6-(4-methylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{4-[(5-cyclopropyl-2-pyridinyl)oxy]benzyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(4-hydroxy-1-{[2-(4-methylphenoxy)-5-pyrimidinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[6-(4-chlorophenoxy)-5-methyl-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine;

N-[(1-{[5-(4-chlorophenoxy)-2-pyrazinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-

3-pyridinyl)carbonyl]glycine; or

N-[(1-{[5-(4-cyclopropylphenoxy)-2-pyrazinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrah ydro-3-pyridinyl)carbonyl]glycine,

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 which is

N-[(1-{[6-(4-chlorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 which is

N-[(1-{[6-(4-cyclopropylphenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrah ydro-3-pyridinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 which is

N-[(4-hydroxy-1-{[6-(3-methylphenoxy)-3-pyridinyl]methyl}-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 which is

N-[(1-{[6-(3-fluorophenoxy)-3-pyridinyl]methyl}-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof.


12. The compound of claim 1 which is

N-[(4-hydroxy-1-{4-[(6-methyl-3-pyridinyl)oxy]benzyl}-2-oxo-1,2,5,6-tetrahydro-3-py ridinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1, having the aforementioned general formula (I'), wherein

W is the formula $-CR^{11}R^{12}CR^{13}R^{14}-$, and the compound is represented by general formula (I):

[Formula 273]



(I)

(wherein in formula (I),

R^{11} is a hydrogen atom, C_{1-4} alkyl, or phenyl,

R^{12} is a hydrogen atom or C_{1-4} alkyl,

provided that R^{11} and R^{12}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane or a 4- to 8-membered saturated heterocycle containing an oxygen atom;

R^{13} is a hydrogen atom, C_{1-4} alkyl, halo-C_{1-4} alkyl, phenyl, benzyl, or phenethyl,

R^{14} is a hydrogen atom or C_{1-4} alkyl,

provided that R^{13} and R^{14}, together with the adjacent carbon atom, optionally form C_{3-8} cycloalkane or a 4- to 8-membered saturated heterocycle containing an oxygen atom,

provided that the aforementioned R^{12} and R^{13}, together with the adjacent carbon atoms, optionally form C_{3-8} cycloalkane;

Y is a single bond or C_{1-6} alkanediyl (one of the carbon atoms in the C_{1-6} alkanediyl is optionally substituted by C_{3-6} cycloalkane-1,1-diyl);

R^2 is C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one group selected from the group consisting of phenyl and benzyl), phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from group α1 of substituents), naphthyl, indanyl, tetrahydronaphthyl, pyrazolyl [the pyrazolyl is substituted by one phenyl (the phenyl is optionally substituted by one C_{1-6} alkyl) and may further be substituted by one C_{1-6} alkyl], imidazolyl (the imidazolyl is

substituted by one phenyl), isoxazolyl [the isoxazolyl is substituted by one phenyl (the phenyl is optionally substituted by one halogen atom)], oxazolyl (the oxazolyl is substituted by one phenyl and may further be substituted by one C_{1-6} alkyl), thiazoyl (the thiazoyl is substituted by one phenyl), pyridyl [the pyridyl is substituted by one group selected from the group consisting of phenyl, phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, cyano, C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), and phenylsulfanyl (the phenylsulfanyl is optionally substituted by one halogen atom)], pyrimidinyl (the pyrimidinyl is substituted by one group selected from the group consisting of cyclohexyl and phenyl), benzothiophenyl, quinolyl, or methylenedioxyphenyl (the methylenedioxyphenyl is optionally substituted by one or two fluorine atoms);

group $\alpha 1$ of substituents consists of a halogen atom, C_{1-6} alkyl {the C_{1-6} alkyl is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl, phenyl, and C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one C_{3-8} cycloalkyl (the C_{3-8} cycloalkyl is optionally substituted by one C_{1-6} alkyl)]}, halo-C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl (the phenyl is optionally substituted by one to three groups which are the same or different and are selected from group $\alpha 2$ of substituents), thienyl, pyrazolyl (the pyrazolyl is optionally substituted by one C_{1-6} alkyl), isoxazolyl, thiazoyl (the thiazoyl is optionally substituted by one or two C_{1-6} alkyls), pyridyl (the pyridyl is optionally substituted by one group selected from the group consisting of C_{1-6} alkyl, halo-C_{1-6} alkyl, C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), quinolyl, C_{1-6} alkoxy [the C_{1-6} alkoxy is optionally substituted by one group selected from the group consisting of C_{3-8} cycloalkyl and phenyl (the phenyl is optionally substituted by one group selected from the group consisting of a halogen atom and C_{1-6} alkyl)], halo-C_{1-6} alkoxy, C_{2-6} alkenyloxy, C_{3-8} cycloalkoxy, phenoxy (the phenoxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, halo-C_{1-6} alkyl,

C_{1-6} alkoxy, and halo-C_{1-6} alkoxy), pyridyloxy (the pyridyloxy is optionally substituted by one group selected from the group consisting of a halogen atom, C_{1-6} alkyl, and halo-C_{1-6} alkyl), and C_{1-6} alkylsulfanyl;
group $\alpha 2$ of substituents consists of a halogen atom, cyano, hydroxy, C_{1-6} alkyl, halo-C_{1-6} alkyl, phenyl, C_{1-6} alkoxy, halo-C_{1-6} alkoxy, C_{1-6} alkylcarbonyl, and di-C_{1-6} alkylaminosulfonyl),
or a pharmaceutically acceptable salt thereof.

14. A medicine comprising the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof as an active ingredient.

15. A PHD2 inhibitor comprising the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof as an active ingredient.

16. An EPO production promoter comprising the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof as an active ingredient.

17. The compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of anemia.

18. The use of compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of anemia.